RTP Mobile Logo
Exploring Key Issues Affecting the Care of Patients with Metastatic Colorectal Cancer with BRAF Mutations (Faculty Presentation)
Released October 2021

Featuring slide presentations and related discussion from Dr Scott Kopetz on cases from the practice of Dr Wells Messersmith. Published October 7, 2021. (Faculty Presentation)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

    LEARNING OBJECTIVES

    • Coordinate comprehensive biomarker analysis for patients diagnosed with metastatic colorectal cancer (mCRC), and use this information to guide evidence-based care.
    • Consider patient and disease characteristics, including the presence of BRAF V600E mutations, to inform the selection of first- and later-line therapy for patients with mCRC.
    • Appreciate published research data documenting the efficacy of the BRAF inhibitor encorafenib in combination with the EGFR inhibitor cetuximab for patients with relapsed/refractory mCRC and a BRAF V600E mutation in order to optimally incorporate this recently approved therapeutic strategy into current clinical algorithms.
    • Recall available and emerging data with investigational strategies currently undergoing evaluation for BRAF-mutant mCRC, and where applicable, refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BRAFmCRC21/Presentations/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Scott Kopetz, MD, PhD
    Professor and Deputy Chair
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AbbVie Inc, Amal Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, Carina Biotech, Daiichi Sankyo Inc, EMD Serono Inc, Flame Biosciences, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, HalioDx, Holy Stone Healthcare Co Ltd, Inivata, Ipsen Biopharmaceuticals Inc, Iylon Precision Oncology, Jacobio Pharmaceuticals Group Co Ltd, Jazz Pharmaceuticals Inc, Lilly, Lutris Pharma, Merck, Mirati Therapeutics, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Redx Pharma Plc, Repare Therapeutics, Servier Pharmaceuticals LLP, Sumitomo Dainippon Pharma Oncology Inc, Xilis; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Biocartis, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Guardant Health, Lilly, Novartis, Sanofi Genzyme; Ownership Interest: Iylon Precision Oncology, Lutris Pharma, MolecularMatch, Navire Pharma.

    Consulting Clinical Investigator

    Wells A Messersmith, MD
    Professor and Head, Division of Medical Oncology
    Associate Director for Translational Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Contracted Research: ALX Oncology, BeiGene Ltd, Bristol-Myers Squibb Company, Exelixis Inc, Experimental Drug Development Centre (Singapore), Immunomedics Inc, Pfizer Inc, Mitsubishi Tanabe Pharma America; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics, Zymeworks.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Pfizer Inc.

    Release date: October 2021
    Expiration date: October 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):